India’s top ranked pharmaceutical company, Sun Pharmaceutical Industries Ltd., reported a weak set of numbers in the third quarter, jaded by continuing pricing pressures in the US and adjustments for tax reforms there.
Net profits plunged by more than 75% to INR3.65bn ($57m), blunted by a one-time deferred tax adjustment of INR5.13bn related...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?